Diagnostics And Consultation Center Convex Ltd. — Clinical Trial Site

93 Registered trials

28 Currently recruiting

Organisation

Diagnostics And Consultation Center Convex Ltd.

Location

Sofiya, Bulgaria

Identifier

ORG-100044957

Address

Ulitsa Sinanishko Ezero 11a, 1680, Bulgaria

Departments

-
3004
301: Cabinet No2
3502:NA
7320: NA
8006:
BG10012
Clinical Pharmacology
Clinical trial Center-Phase I Unit
Consulting Room Cardiology
Diagnostic Consultative Center
Diagnostic Consultative Center Convex
Diagnostic Consultative Center Convex EOOD
Diagnostics And Consultation Center Convex Ltd
Gastroenterologist
Gastroenterology
Internal Medicine
Medical centre
N/A
NA
Neurology
Not applicable
pneumology

Clinical trials at this site (93)

Search interface

A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
CHAPTER-3 – A randomised clinical trial to assess efficacy and safety of deucrictibant treatment in prophylaxis against HAE attacks in adult… Ended

2024-516247-62-00 Hereditary Angioedema 5 2025-03-10
A Long-term trial to learn about a study drug (STAR-0215) in adults with hereditary angioedema Ended

2023-506540-16-01 Hereditary Angioedema 4 2025-01-20
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
A study looking at how effective and safe AZD7798 is in people with Crohn's disease Ended

2023-510487-12-00 Crohn's Disease 4 2024-11-29
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended

2023-509302-30-00 Hypertriglyceridemia 5 2024-11-04
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended

2023-509300-14-00 Severe hypertriglyceridemia (SHTG) 5 2024-10-31
A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus Ended

2024-510584-37-00 Systemic Lupus Erythematosus 4 2024-10-22
A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Ended

2023-508039-29-00 Moderate-to-severe Asthma 4 2024-09-16
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely… Ended

2023-504719-34-00 Moderate to Severly Active Ulcerative Colitis 5 2023-02-21
Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended

2023-508498-97-00 Systemic Lupus Erythematosus 5 2023-02-03
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Multiple Sclerosis 5 2022-06-22
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis Ended

2023-506359-68-00 Active Proliferative Lupus Nephritis 5 2022-04-08
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended

2023-504734-21-00 Psoriatic arthritis (PsA) 5 2021-08-30
ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Ended

2024-515156-21-00 Ulcerative Colitis 5 2020-01-09
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504718-31-00 Moderately to Severely Active Ulcerative Colitis 10 2019-10-19
Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP Ended

2024-515386-34-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2025-05-29
Phase 1 clinical trial to evaluate the safety, tolerability and pharmacokinetics of multiple daily doses of IM-250 in healthy volunteers. Ended

2024-519482-22-00 Healthy Volunteers 3 2025-04-30
Randomized, open-label clinical trial (Phase 1) to evaluate safety, tolerability, pharmacokinetics and food effects of a single dose of IM-2… Ended

2024-518155-37-00 Healthy volunteers 3 2025-02-14
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended

2023-507680-19-00 Sjögren’s Syndrome 4 2024-11-28